Clinicopathological characteristics of patients with mid-low rectal cancer
Detailed clinicopathological data of the 378 rectal cancer patients who underwent anterior resection are shown in Table 1. In the present study, 74 cases with a DRM of ≤1cm were compared to 304 cases with a DRM of >1cm. The mean DRM length was 0.8±0.3 cm in the DRM of ≤1 cm group and 2.6±1.0 cm in the DRM of >1 cm group. The mean distance from the anal verge in the DRM of ≤1 cm group was significantly different from that in the DRM of >1 cm group (8.3±3.3 vs. 9.3±2.8cm, p=0.017). The groups were comparable in gender, age, preoperative CRT, tumor differentiation, and lymphovascular invasion. There were more patients with pT1/T2 in the DRM of ≤1 cm group (48.7 vs. 21.0%; p<0.001), as well as more TNM p-stage Ⅰ/Ⅱ ( 62.2 vs. 53.9%, p<0.001), respectively. There was a large proportion of the perineural invasion in the DRM of ≤1 cm group compared with the DRM of >1 cm group (8.1 vs. 5.3%; p=0.037). Preoperative chemoradiotherapy was administered to 16.2% (12/74) of the patients with a DRM of ≤1cm and 10.5% (32/304) of the patients with a DRM of >1cm, respectively (p=0.171).
After applying propensity-score matching strategy (1:1), 65 patients with a DRM of ≤1cm were matched to 65 patients with a DRM of >1cm. Form Table 1, there were no significant differences in bassline clinicopathological data between two groups (p>0.05).
Table 1. Features of the patients in the different subgroups.
Variables
|
Before matching
|
After matching
|
DRM≤1cm (n=74)
|
DRM>1cm (n=304)
|
p
|
DRM≤1 cm (n=65)
|
DRM>1 cm (n=65)
|
p
|
Distal margin (cm), median (range)
|
1.0 (0.2-1.0)
|
2.5 (1.2-6.0)
|
|
1.0 (0.2-1.0)
|
2.0 (1.2-6.0)
|
|
Age (mean ± sd)
|
63±10.9
|
60±10.3
|
0.055
|
63.2±11.1
|
63.9±8.9
|
0.709
|
Sex
|
|
|
0.932
|
|
|
0.598
|
Male
|
40
|
166
|
|
33
|
36
|
|
Female
|
34
|
138
|
|
32
|
29
|
|
Tumor distance from AV (cm, range)
|
8.3±3.3
|
9.3±2.8
|
0.017
|
8.5±3.4
|
8.5±2.5
|
1.000
|
Pathologic T stage
|
|
|
<0.001
|
|
|
0.932
|
T1
|
12
|
18
|
|
8
|
6
|
|
T2
|
24
|
46
|
|
21
|
20
|
|
T3
|
36
|
188
|
|
34
|
37
|
|
T4
|
2
|
52
|
|
2
|
2
|
|
TNM stage
|
|
|
<0.001
|
|
|
0.519
|
Ⅰ
|
28
|
50
|
|
23
|
17
|
|
Ⅱ
|
18
|
114
|
|
18
|
20
|
|
Ⅲ
|
28
|
140
|
|
24
|
28
|
|
Preoperative CRT
|
|
|
0.171
|
|
|
0.435
|
Yes
|
12
|
32
|
|
10
|
7
|
|
No
|
62
|
272
|
|
55
|
58
|
|
Tumor differentiation
|
|
|
0.745
|
|
|
0.739
|
Well
|
4
|
20
|
|
4
|
3
|
|
Moderately
|
56
|
242
|
|
49
|
54
|
|
Poorly
|
12
|
36
|
|
10
|
7
|
|
Uncertainly
|
2
|
6
|
|
2
|
1
|
|
Perineural invasion, n (%)
|
4 (5.4)
|
16 (5.3)
|
0.037
|
2 (3.1)
|
7 (10.8)
|
0.167
|
Lymphovascular invasion, n (%)
|
8 (10.8)
|
44 (14.5)
|
0.412
|
8 (12.3)
|
8 (12.3)
|
1.000
|
Data are given as number of patients with percentage. DRM, distal resection margin; AV, anal verge; CRT, chemoradiotherapy.
Oncologic results in relation to the different distal margins regardless of NCRT
Before propensity-score matching, the median follow-up period was 78 months (range,3–126 months) in patients with a DRM of ≤1 cm and 70 months (range, 8-132 months) in patients with a DRM of >1cm (p=0.646, Table 2). During follow-up, 5 out of 74 (6.8%) patients with a DRM of ≤1 cm developed local recurrence, and 18 out of 304 (5.9%) patients with a DRM of >1cm had local recurrence (p=0.920). The distant metastasis rate was similar between the two groups (8.1 vs. 13.2%, p=0.183). After propensity-score matching (Table 2), the median follow-up period was 79 months (range,3–126 months) in patients with a DRM of ≤1 cm and 65 months (range, 15-118 months) in patients with a DRM of >1cm (p=0.122). During follow-up, the local recurrence rate was the same in both groups (7.7 vs. 7.7%, p=1.000). No significant difference was observed in distant metastasis between the two groups (9.2 vs. 15.4%, p=0.286).
Table 2. Oncologic results in relation to the different distal margins.
|
Before matching
|
After matching
|
Variable
|
DRM≤1cm
|
DRM>1cm
|
p
|
DRM≤1cm
|
DRM>1cm
|
p
|
(n=74)
|
(n=304)
|
(n=65)
|
(n=65)
|
Median follow-up, months (range)
|
78 (3–126)
|
70 (8-132)
|
0.646
|
79 (3–126)
|
65 (15-118)
|
0.122
|
local recurrence (%)
|
5/74 (6.8)
|
18/304 (5.9)
|
0.92
|
5/65 (7.7)
|
5/65 (7.7)
|
1.000
|
Metastasis (%)
|
6/74 (8.1)
|
40/304 (13.2)
|
0.183
|
6/65 (9.2)
|
10/65 (15.4)
|
0.286
|
5-y DFS (%)
|
92.8
|
81.3
|
0.128
|
88.1
|
78.2
|
0.162
|
5-y OS (%)
|
83.7
|
82.2
|
0.892
|
84.5
|
84.9
|
0.420
|
Data are given as number of patients with recurrence ⁄ total number of patients. DRM, distal resection margin; DFS, disease-free survival; OS, overall survival.
The patterns of local recurrence and distant metastasis in the two groups are presented in Table 3. With regard to local recurrence, pelvic lymph nodes recurrence was more common than anastomotic recurrence in both groups. As for distant metastasis, the lung was the most common metastatic organ in two groups. Four patients had lung metastases, 2 patients had simultaneous lung and liver metastases, and another patient had paraaortic lymph nodes relapse in the DRM of ≤1 cm group. Similarly, there were 16 lung metastases, 12 liver metastases, 8 simultaneous lung and liver metastases, 2 paraaortic lymph nodes relapse, and 2 ovary metastases in the DRM of >1 cm group.
Table 3. Patterns of local recurrence and distant metastasis in the subgroups.
Recurrence sites
|
DRM≤1cm (n=74)
|
DRM>1cm (n=304)
|
LR, n (%)
|
|
|
Anastomotic
|
2 (2.7)
|
6 (2.0)
|
Pelvic LN
|
3 (4.1)
|
12 (3.9)
|
DM, n (%)
|
|
|
Liver
|
0 (0.0)
|
12 (3.9)
|
Lung
|
4 (5.4)
|
16 (5.3)
|
Liver and lung
|
2 (2.7)
|
8 (2.6)
|
Paraaortic lymph nodes
|
1 (1.4)
|
2 (0.7)
|
Ovary
|
0 (0.0)
|
2 (0.7)
|
LR, Local recurrence; LN, lymph node; DM, Distant metastasis; DRM, distal resection margin.
Before propensity-score matching, the DFS rate was 92.8% in patients with a DRM of≤1 cm group and 81.3% in patients with a DRM of >1 cm group (p= 0.128). The OS rate at 5 years was 83.7% in the DRM of ≤1 cm group and 82.2% in the DRM of >1 cm group (p=0.892, Fig.1). After propensity-score matching, there were also no significant differences in DFS (88.1 vs. 78.2%; P=0.162) and OS (84.5vs. 84.9%; P=0.420) between the DRM of ≤1 cm group (n=65) and the DRM of >1 cm group (n=65), respectively (Fig.1).
Subgroup analysis of overall survival stratified by DRM and the use of NCRT
Considering the influence of NCRT on the distance of tumor invasion, we analyzed the effect of DRM on overall survival of rectal cancer patients according to whether preoperative chemoradiotherapy was adopted.
A total of 44 patients received preoperative chemoradiotherapy. In this cohort, the 5-year local recurrence rates were similar between the DRM of ≤1 cm group and the DRM of >1 cm group ( 8.3 vs. 1.9%, p=0.118). The estimated 5-year DFS rate was not significantly different between the two groups (83.3 vs. 68.8%, p=0.298, Table 4 and Fig. 2).
Three hundred thirty-four patients received surgery alone without NCRT. Nobody developed local recurrence in 62 patients with a DRM of ≤1 cm, but 10 patients experienced local recurrence out of 272 patients with a DRM of >1 cm (0 vs. 3.7%, p=0.150). Consistent with the neoadjuvant chemoradiation group, there was no significant difference between the two groups (93.5 vs. 83.8%, p=0.172, Table 4 and Fig. 3).
Table 4. Kaplan-Meier estimates of 5-y LR and 5-y DFS stratified by DRM and NCRT.
|
Variable
|
Group (n)
|
No. of events (%)
|
p (Log-rank)
|
NCRT (n=44)
|
LR
|
DRM≤1cm (12)
|
1 (8.3)
|
0.118
|
|
|
DRM>1cm (32)
|
6 (1.9)
|
|
|
DFS
|
DRM≤1cm (12)
|
10 (83.3)
|
0.298
|
|
|
DRM>1cm (32)
|
22 (68.8)
|
|
Surgery alone (n=334)
|
LR
|
DRM≤1cm (62)
|
0 (0.0)
|
0.150
|
|
|
DRM>1cm (272)
|
10 (3.7)
|
|
|
DFS
|
DRM≤1cm (62)
|
55 (93.5)
|
0.172
|
|
|
DRM>1cm (272)
|
226 (83.8)
|
|
LR, local recurrence; DFS, disease-free survival; NCRT, neoadjuvant chemoradiotherapy; DRM, distal resection margin.